Adaptimmune announces collaboration with MSD to evaluate KEYTRUDA® (pembrolizumab)
Adaptimmune announced a clinical trial collaboration agreement with Merck for the assessment of Adaptimmune’s NY-ESO SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in combination with MSD’s anti-PD-1 inhibitor, KEYTRUDA® (pembrolizumab), in patients with multiple myeloma. October 27, 2016